ZA200300125B - Process for preparing (-)menthol and similar compounds. - Google Patents
Process for preparing (-)menthol and similar compounds. Download PDFInfo
- Publication number
- ZA200300125B ZA200300125B ZA200300125A ZA200300125A ZA200300125B ZA 200300125 B ZA200300125 B ZA 200300125B ZA 200300125 A ZA200300125 A ZA 200300125A ZA 200300125 A ZA200300125 A ZA 200300125A ZA 200300125 B ZA200300125 B ZA 200300125B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- lipase
- process according
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 87
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 title description 33
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 title description 23
- 229960004873 levomenthol Drugs 0.000 title description 11
- 238000004519 manufacturing process Methods 0.000 title description 7
- 102000004190 Enzymes Human genes 0.000 claims description 45
- 108090000790 Enzymes Proteins 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 45
- 108090001060 Lipase Proteins 0.000 claims description 39
- 102000004882 Lipase Human genes 0.000 claims description 39
- 239000004367 Lipase Substances 0.000 claims description 36
- 235000019421 lipase Nutrition 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 239000007795 chemical reaction product Substances 0.000 claims description 31
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 239000003054 catalyst Substances 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 108090000371 Esterases Proteins 0.000 claims description 11
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002002 slurry Substances 0.000 claims description 11
- 230000000707 stereoselective effect Effects 0.000 claims description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 8
- 102000043296 Lipoprotein lipases Human genes 0.000 claims description 8
- 241001661345 Moesziomyces antarcticus Species 0.000 claims description 8
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 7
- 239000006227 byproduct Substances 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 6
- 241000235403 Rhizomucor miehei Species 0.000 claims description 6
- 240000006439 Aspergillus oryzae Species 0.000 claims description 5
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 241000589774 Pseudomonas sp. Species 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 4
- 229940116333 ethyl lactate Drugs 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 241000589513 Burkholderia cepacia Species 0.000 claims description 3
- -1 Novozyme 868 Proteins 0.000 claims description 3
- 108010073038 Penicillin Amidase Proteins 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 241001453380 Burkholderia Species 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 102000013392 Carboxylesterase Human genes 0.000 claims description 2
- 108010051152 Carboxylesterase Proteins 0.000 claims description 2
- 241000146387 Chromobacterium viscosum Species 0.000 claims description 2
- 241000222175 Diutina rugosa Species 0.000 claims description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 claims description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 claims description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 2
- 241000498617 Mucor javanicus Species 0.000 claims description 2
- 108010084311 Novozyme 435 Proteins 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 241000193390 Parageobacillus thermoglucosidasius Species 0.000 claims description 2
- 240000000064 Penicillium roqueforti Species 0.000 claims description 2
- 235000002233 Penicillium roqueforti Nutrition 0.000 claims description 2
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 2
- 241000588264 Rhizopus javanicus Species 0.000 claims description 2
- 241000235545 Rhizopus niveus Species 0.000 claims description 2
- 240000005384 Rhizopus oryzae Species 0.000 claims description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims description 2
- 241000235015 Yarrowia lipolytica Species 0.000 claims description 2
- 241000179532 [Candida] cylindracea Species 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 2
- 239000010953 base metal Substances 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- HASGOCLZFTZSTN-UHFFFAOYSA-N cyclohexane;hexane Chemical compound CCCCCC.C1CCCCC1 HASGOCLZFTZSTN-UHFFFAOYSA-N 0.000 claims description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 claims description 2
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 claims description 2
- 210000003918 fraction a Anatomy 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 239000003350 kerosene Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- HETCEOQFVDFGSY-UHFFFAOYSA-N Isopropenyl acetate Chemical compound CC(=C)OC(C)=O HETCEOQFVDFGSY-UHFFFAOYSA-N 0.000 claims 1
- 108010056079 Subtilisins Proteins 0.000 claims 1
- 102000005158 Subtilisins Human genes 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 23
- 229940041616 menthol Drugs 0.000 description 21
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 14
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 10
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 8
- 239000005844 Thymol Substances 0.000 description 7
- 229960000790 thymol Drugs 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 238000004817 gas chromatography Methods 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 229910052759 nickel Inorganic materials 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010093096 Immobilized Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940075966 (+)- menthol Drugs 0.000 description 2
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101001003495 Pseudomonas fluorescens Lipase Proteins 0.000 description 2
- 101001064559 Pseudomonas fluorescens Lipase Proteins 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- NFLGAXVYCFJBMK-DTWKUNHWSA-N (+)-menthone Chemical compound CC(C)[C@H]1CC[C@H](C)CC1=O NFLGAXVYCFJBMK-DTWKUNHWSA-N 0.000 description 1
- 229930007506 (+)-menthone Natural products 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229910019440 Mg(OH) Inorganic materials 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000009904 heterogeneous catalytic hydrogenation reaction Methods 0.000 description 1
- 238000009905 homogeneous catalytic hydrogenation reaction Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002729 menthone derivatives Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
$ .
PROCESS FOR PREPARING (-)MENTHOL
AND SIMILAR COMPOUNDS
THIS invention relates to a process for producing (-)-menthol and similar compounds. (-)-Menthol is one of the world's largest selling flavour compounds, with a production of about 11800 tons per annum. Its peppermint flavour and cooling sensation are used in many products, primarily in mentholated cigarettes and oral hygiene products, such as toothpaste, mouthwash and chewing gum.
Pharmaceutical and healthcare products use menthol in a variety of product types, such as cough lozenges, shaving cream and topical analgesics.
Owing to seasonal variations and poor farming practices, the availability of natural menthol from the largest supplying countries, India and China, is sometimes erratic. In addition to this, only a limited amount of peppermint can be planted, thus limiting the supply of natural menthol. The remainder of the demand for menthol is met by synthetic menthol.
CONFIRMATION GOPY
R WO 02/04384 PCT/IB01/01008 ’ Organoleptically, natural and synthetic menthol are completely interchangeable; any slight differences have been largely eliminated through product development. Moreover, synthetic menthol has a purer and more consistent taste and odour profile since it does not contain the impurities present in natural menthol.
There is always a need for new processes for the production of (-)-menthol and similar compounds.
According to the invention there is provided a process of separating a single desired stereoisomer from a racemic mixture of eight stereoisomers of a compound of the formula lil "OH
R4
I wherein R, represents an isopropanol group, an isopropyl group or an isopropylene group, including the steps of: ’ (1) contacting the racemic mixture in a suitable organic solvent with an esterifying agent and a stereospecific enzyme which stereoselectively ) esterifies the -OH group of the desired stereoisomer, for a time sufficient to convert a desired percentage of the desired stereoisomer to a ] compound of the formula IV
I
0 Ry
Ry
Iv wherein Ry is as defined above and Ry is an alkyl or an ary! group, to give a first reaction product including the compound of the formula 1V, the organic solvent, the unconverted stereoisomers of the compound of the formula lil, excess esterifying agent and by-products of the reaction; and (2) separating the compound of the formula IV from the first reaction product.
Step (2) preferably comprises the sub-steps of: (2)(a) separating the first reaction product from the enzyme; (2b) removing from the first reaction product the organic solvent, the excess esterifying agent, and the by-products of the reaction to give a second reaction product including the compound of the formula IV .and the unconverted stereoisomers of the compound of formula lll ; and (2)(c) separating the compound of the formula IV from the second reaction product leaving a third reaction product containing the unconverted stereoisomers of the compound of the formula Ill.
The process of the invention preferably includes a further step, step (3) of:
A WO 02/04384 PCT/IB01/01008 ) (3) racemizing the unconverted stereoisomers of the compound of the formula [ll in the third reaction product to give a fourth reaction product ) containing a mixture of all eight stereoisomers of the compound of the formula Ill and recycling the fourth reaction product to step (1).
The process of the invention preferably includes a further step, step (4) of: (4) hydrolysing the compound of the formula IV to give the desired sterecisomer of the compound of the formula ll.
In the process of the invention, when R; is an isopropanol group or an isopropylene group, before or after step (4), the compound of the formula IV or the desired stereoisomer of the compound of the formula lll may be subjected to a reduction step to convert Ry to an isopropyl group.
The process of the invention preferably includes the following steps, prior to step (1) of: (a) reacting a compound of the formula
Ra “OR,
I wherein R, represents a methyl or a hydroxymethyl group, and Rj represents
H, a base metal, a benzyl group or an allyl group, with an alkylating agent in the presence of a catalyst to give a compound of the formula ll
A WO 02/04384 PCT/IB01/01008
Ra “OR,
Ry
II wherein R,, R, and Rj; are as defined above; and (b) hydrogenating the compound of the formula I in the presence of a catalyst to give a racemic mixture of the eight stereoisomers of the compound of the formula lil.
The crux of the invention is a process of separating a single desired stereoisomer of a compound of the formula Ill from a racemic mixture of the eight stereoisomers of the compound of the formula Ill, by esterification using a stereospecific enzyme.
This process step may form part of a larger process as described below.
The first step, step (a) of the process is to alkylate a compound of the formula ) to yield a compound of the formula li, using an alkylating agent such as propylene, isopropanol or acetone, in the presence of a catalyst.
A WO 02/04384 PCT/IB01/01008 ) The catalyst may be a Lewis acid catalyst such as AlCls, SnCls, BF3, ZnCl, or
FeCls, or a Bronsted acid such as HCI, HF, H2SO4 or HaPO,; or a suitable supported catalyst such as Envirocat EPIC which is a polyphosphoric acid on a support, or Envirocat EPZ 10 which is a ferric chloride on a support; or a solid phosphoric acid; or a suitable zeolite catalyst which is the preferred catalyst.
Step (a) may be carried out in the presence of a solvent such as a chlorinated solvent, e.g dichloromethane, chloroform or dichloroethane, but the presence of a solvent is not essential.
Step (a) may be carried out as a batch reaction or as a continuous gas or liquid phase reaction.
In step (a), the reaction temperature during and after the reaction may be any temperature below 450°C.
Step (a) may be carried out in air or under an inert atmosphere such as argon or nitrogen.
The compound of the formula | is preferably m-cresol, and thus the compound of the formula Hl is preferably thymol.
At the end of step (a), the catalyst is removed or deactivated, and any solvent present is removed. The required compound of the formula Il is isolated from the reaction mixture, for example by distillation. The unreacted alkylating agent and reaction by-products may be recycled to step (a).
The second step, step (b) of the process is to reduce the compound of the formula Il to a racemic mixture of the eight stereoisomers of the compound of the formula Ill, by hydrogenation using hydrogen gas over a suitable catalyst.
iy
The catalyst may be any catalyst typically used in homogeneous catalytic . hydrogenations such as Pd(OAc), or in heterogenous catalytic hydrogenations such- as supported palladium, platinum, rhodium, ruthenium, nickel, sponge nickel and 2CuQ.Cr,0;.
The preferred catalyst is a nickel catalyst.
The catalyst loading may be from 0,01 to 20%, preferably from 0,5 to 5%.
Step (b) may be carried out with or without a solvent. If a solvent is used, it may be any solvent typically used for catalytic hydrogenation, for example a hydrocarbon or aqueous caustic. .
Step (b) is preferably carried out at an elevated temperature of from 80°C to 300°C inclusive, preferably from 160°C to 200°C inclusive.
Step (b) is carried out using a hydrogen pressure which is below 50 bar, preferably between 5 and 35 bar inclusive.
When the compound of the formula Il is thymol, there is formed a racemic mixture of the four pairs of diastereomeric isomers of menthol, viz (+)-menthol, (£)-isomenthol, (+)-neomenthol” and (*)-necisomenthol, as well as two intermediates (+)-menthone and (t)-isomenthone.
At the end of step (b), the catalyst is removed, e.g by filtration, or is deactivated, and any solvent present is removed.
The next step of the process of the invention, step (1), is the key step of the process.
y WO 02/04384 PCT/IB01/01008
The racemic mixture of the eight stereoisomers of the compound of the formula
Ill from the hydrogenation step (step (b)) is contacted in a suitable organic solvent with an esterifying agent and with a stereospecific enzyme which stereoselectively esterifies the -OH group of the desired sterecisomer of the compound of the formula lll, for a time sufficient to convert a desired percentage of the desired stereoisomer to a compound of the formula IV, to give a first reaction product including the compound of the formula IV, the organic solvent, the unconverted stereoisomers of the compound of the formula lil, excess esterifying agent, and by-products of the reaction.
The reaction is a stereoselective esterification of a desired stereoisomer of the compound of the formula Ili, with the other stereoisomers of the compound of the formula Ill remaining substantially unchanged, although small amounts of the other stereoisomers may also be esterified by the enzyme.
When R; of the compound of the formula lll is an isopropyl group, the compound corresponds to menthol which consists of eight stereoisomers. The B desired stereoisomer of menthol is the (-)-isomer, which can be selectively esterified using a suitable enzyme to the (-)-menthyl ester.
The suitable organic solvent may be any solvent typically used for enzyme catalysed esterification reactions, including isooctane; n-heptane; decane, methyl cyclohexane; t-butyl methyl ether; xylene; kerosene (C5-C6 paraffins, keraso! 60/115), (C7-C8 paraffins, kerasol 94/125); pentane; cyclohexane; hexane: benzene; butanol; toluene; isopropanol; ethyl lactate; and acetone.
The preferred organic solvent is n-heptane. ‘The amount of the organic solvent used relative to the racemic mixture of the compound of the formula Ill is preferably in the range of from 5% to 80% racemic mixture to 95% to 20% organic solvent on a volume basis.
0.
When the organic solvent is n-heptane, the racemic mixture is preferably used in an amount of 20% v/v in the n-heptane.
The esterifying agent may be any suitable esterifying agent such as for example vinyl acetate, butyl acetate, octanoic acid, isopropeny! acetate, vinyl butyrate, ethyl lactate and ethyl acetate.
The preferred esterifying agent is vinyl acetate.
The esterifying agent may be used in an molar ratio to the desired stereoisomer of the compound of the formula [lI of 0,5:1 up to 30:1. The preferred molar ratio of the esterifying agent to the desired stereocisomer of the compound of the formula lil is about 2:1 when vinyl acetate is used as the esterifying agent.
The enzyme is a stereospecific enzyme which stereoselectively esterifies the -OH group of the compound of the formula ill.
The enzyme may be contained within a microorganism, or secreted into a medium required for microorganism growth, or may be available commercially in semi-purified or purified form. Microorganisms can also be provided with the ability to produce a suitable enzyme through the process of genetic engineering of the microorganism.
Examples of enzymes and microorganisms that are capable of performing this esterifying process include those exhibiting lipase, esterase or protease-like activity.
Suitable enzymes include, but are not limited to:
Enzymes supplied by Fluka: Candida cylindracea lipase, lipase Hog pancreas, lipase Pseudomonas fluorescens, lipase Aspergillus oryzae, lipase Rhizopus niveus, lipase Rhizomucor miehei, lipase Candida antarctica, lipase Mucor javanicus, lipase Rhizopus arrhizus, lipase Penicillium roqueforti, lipase
Candida lipolytica, lipoprotein lipase Pseudomonas sp., type B, lipoprotein lipase Pseudomonas cepacia, lipoprotein lipase Chromobacterium viscosum, esterase Bacillus thermoglucosidasius, esterase Bacillus stearothermophilus, esterase Mucor miehei, esterase hog liver,
Enzymes supplied by Altus: Candida rugosa lipase, lipase Mucor miehei,
Candida antarcitica B lipase, Candida antarctica A lipase, Chiro-CLEC-CR,
Chiro-CLEC-CR (slurry), porcine liver esterase, Penicillin acylase, Subtilisin
Carlsberg, Chiro-CLEC-BL (slurry), Chiro-CLEC-PC (slurry), Chiro-CLEC-EC (slurry), Aspergillus oryzae protease, PeptiCLEC-TR (slurry);
Enzymes supplied by Recombinant Biocatalysis: ESL-001-07, ESL-001-01,
ESL-001-01 with stabiliser, ESL-001-02, ESL-001-03, ESL-001-05;
Enzymes supplied by Boehringer-Mannheim: Chirazyme L4 (Pseudomonas sp.), Chirazyme L5 (Candida antarctica fraction A), Chirazyme L1 (Burkholderia), Chirazyme L6 (Porcine pancreas), Chirazyme L7, Chirazyme
L8;
Enzymes supplied by Gist-Brocades: Naproxen esterase, Lipomax, Genzyme,
Lipoprotein lipase;
Enzymes supplied by Novo: Novozyme 868, Novozyme 435, immobilised
Candida antarctica lipase, Nagase enzyme, Lipase A-10FG (Rhizopus javanicus); :
Enzymes supplied by Amano: Amano AYS, Amano PS, Amano PSD, Amano
AKD11, Amano AKD111.
The preferred enzyme is Amano AK lipase enzyme supplied by Amano of
Japan.
The enzyme may be used either in the free form or immobilized on a suitable support which may be diatomaceous earth.
The enzyme is preferably used in an amount of from 1g/l to 60g/l of the } reaction mixture, i.e the racemic mixture of the eight stereoisomers of the compound of the formula lll, the suitable organic solvent and the esterifying agent.
The resolution step is preferably carried out at a temperature of from 20°C to 100°C inclusive and at atmospheric or higher pressure. When the enzyme is
Amano AK, the preferred reaction temperature is about 50°C.
The resolution reaction is continued for a time sufficient to convert a desired percentage of the desired stereocisomer of the compound of the formula lll to the compound of the formula IV. Generally, it is desirable that as much as possible of the desired sterecisomer is converted to the compound of the formula IV without the reaction proceeding to the esterification of the other stereoisomers present in the racemic mixture.
The reaction time is preferably about 24 hours or less when the reaction is performed in batch mode.
The next step, step (2)(a) of the process of the invention is to separate the first reaction product from the enzyme so that the enzyme can be recycled. This may be achieved for example by centrifugation or by filtration.
A major advantage of the process of the invention is that it is possible to recycle the enzyme a number of times to the resolution step, so as to improve the economics of the process.
The necessity for enzyme recycle may be eliminated by use of the enzyme in a continuous system wherein the enzyme is retained within a reactor. The racemic mixture of the compound of the formula lll, the organic solvent and the esterifying agent as described above, are fed into the reactor, wherein the desired stereoisomer of the compound of the formula lll is esterified to the compound of the formula IV to form the first reaction product. The first reaction product typically exits the reactor at a similar rate to the inlet feed, for further processing. The enzyme may typically be retained within the reactor through the use of membranes, or by immobilisation onto a support material, or through stabilisation by cross-linking.
The next step, step (2)(b) of the process of the invention is to remove the organic solvent, the excess esterifying agent and any by-products, to give a second reaction product including the compound of the formula IV and the ’ unconverted stereoisomers of the compound of the formula lll. This may be carried out by distillation in which the organic solvent, e.g the n-heptane and the excess esterifying agent, e.g the vinyl acetate, are taken off at the top of the column as a single stream and recycled back to suitable storage tanks for later re-use.
The next step, step (2)(c) of the process of the invention is to separate the compound of formula IV from the second reaction product leaving a third reaction product containing the unconverted stereoisomers of the compound of the formula lll. This separation may be achieved by distillation.
In the compound of the formula IV, when Ry is not an isopropyl group, the R, group can, through a reduction process, be converted to an isopropyl group, either at this stage, or subsequent to hydrolysis of the ester group as described below. This results in the production of the desired stereoisomer of menthyl ester, or subsequent to hydrolysis, in the production of the desired stereoisomer of menthol.
The next step, step (3) of the process of the invention is to racemise the unconverted stereoisomers in the third reaction product to give a fourth "reaction product containing a mixture of all eight sterecisomers of the compound of the formula Ill and recycling this to the resolution step of the process.
The racemisation may be achieved over a suitable catalyst with or without hydrogen gas, with or without a solvent, and at atmospheric or greater pressure.
The step may be carried out with or without a solvent. If a solvent is used, the solvent may be any solvent typically used for catalytic hydrogenation, most typically a hydrocarbon or aqueous caustic.
The catalyst used may be any catalyst typically used in homogeneous catalytic hydrogenations such as Pd(OAc), and Ru(PPh;);Cl;, or in heterogeneous catalytic hydrogenations such as supported palladium, platinum, rhodium, ruthenium, nickel, sponge nickel and 2CuQ.Cr,0;, or a solid oxide such as celite, CuO, CrO;, CoO, SiO, Al,O,;, Ba(OH),, MnO, Al(iOPr)3, LnO,, ZrO and the zeolites.
The reaction may be carried out at any temperature between 80°C and 300°C inclusive, preferably at a temperature between 180°C and 220°C inclusive.
The hydrogen pressure may be any pressure below 50 bar, preferably between 5 and 35 bar inclusive.
The catalyst loading may be between 0,01 and 20%, preferably between 0,05 and 5%.
At the end of the step, the catalyst is removed or deactivated, and any solvent present is removed.
This racemisation step may be carried out in conjunction with step (b), i.e the hydrogenation step, where appropriate. ~The next step, step (4) of the process of the invention is to hydrolyse the compound of the formula IV to the desired sterecisomer of the compound of : the formula lll. The reaction may be carried out in the presence of a base which may be a salt of a lower aliphatic alcohol such as sodium methoxide or sodium ethoxide, a metal hydroxide such as KOH, NaOH, or Mg(OH),, or amine bases such as NH,OH.
The reaction may be carried out in any solvent typically used in hydrolysis reactions, such as for example a lower aliphatic alcohol or water.
Combinations of the solvents may also be used.
The reaction temperature may be any temperature below the boiling point of the chosen solvent or the reflux temperature of the mixture at the pressure at which the reaction is carried out. :
In the compound of the formula IV, where Ry is an isopropyl group, hydrolysis of this compound ((-)-menthy! ester) results in the production of (-)-menthol.
As a final step, the desired isomer of the compound of the formula lll may be purified to the desired purity by, for example, distillation or crystallisation.
Experimental Work
The results of various experiments carried out in relation to the process of the invention are set out below.
Example 1 m-Cresol (2,0 g) and o-phosphoric acid (4 mol e.g 8,5 g) were placed in a round bottom flask and heated to 85°C. Isopropanol (1,11 g) was added dropwise over 30 minutes. The reaction was then cooled to 25°C, and the organic phase extracted into toluene (20 ml). NMR analysis of the concentrated organic fraction indicated a 10% conversion of m-cresol to thymol.
Example 2
Thymol (4,20 g), cyclohexane (50 ml) and 5% PY¥C (0,40 g) were placed in a 300 ml Parr autoclave reaction chamber. Once sealed, the chamber was flushed with N, (g) before charging with H, (g) (20 bar). The reaction was heated to 180°C and the reaction was allowed to proceed for 2 hours. The reaction was then allowed to cool to room temperature, the pressure inside the reactor was released and the reaction mixture filtered to give a mixture of menthol stereoisomers (100% conversion thymol, 80% selectivity to menthols).
Example 3
In 2 ml vials, 10 or 100 mg of Pseudomonas cepacia lipase (Fluka),
Pseudomonas fluorescens lipase (Fluka), penicillin acylase (Altus), subtilisin
Carlsberg (Altus), Aspergillus oryzae protease and PeptiCLEC-TR slurry (Altus) were weighed. To this cyclohexane, hexane, pentane or heptane (962,72 pl) were added. Isomeric menthol (23 pl) and vinyl acetate (14,28 wl) were also added. These vials were incubated at 30°C or 37°C for 2 or 48 hours. Enzyme was then removed from the mixture by centrifugation.
Samples were analysed by gas chromatography (GC). An individual peak found on each of the chromatograms was identified as that of (-)-menthyl acetate by comparison with the corresponding retention time of a standard sample of (-)-menthyl acetate.
Example 4
Lyophilised Amano AK (a Pseudomonas fluorescens lipase enzyme) was obtained from Amano Pharmaceutical Co. (Japan). Concentrated liquid menthol was produced by the hydrogenation of thymol. The menthol contained four diastereomeric pairs of menthols, namely (x)-menthol (51%), (2)-isomenthol (14%), (x£)-neomenthol (29%) and (2)-neoisomenthol (2%). A volume of 1m! was added to sealed batch reactors. Vinyl acetate (54 pl) was added at a 2:1 molar ratio to (-)-menthol. Heptane was added as solvent to a final reaction volume of 5 ml. These reactors were incubated in silicon oil baths at 50°C and stirred on a stirring hot plate. Batch times, unless otherwise stated were 24 hours. The reaction mixture was then centrifuged to separate the products from the enzyme. The supernatant was analysed by GC (%em/m analysis). Of the available (-)-menthol, 100% was converted to (-)-menthyil acetate, at an ee of 98%. The enzyme was recycled a total of 150 times by washing with heptane and adding fresh substrate (liquid menthol, vinyl acetate and heptane) after every recycle. An amount of menthyl acetate equivalent to 185 g of (-)-menthol was produced by this process.
Example 5
Amano AK lipase enzyme was dissolved in phosphate buffer (5 mM, pH 7) before adding Celite 535 (in a ratio of 1:2). The mixture was frozen at -80°C for 5 minutes and then freeze-dried for 24 hours to produce immobilized enzyme. A substrate mixture containing 15,5% (v/v) of liquid menthol and 5,5% (v/v) vinyl acetate and 79% (v/v) of n-heptane was prepared. The mixture was pumped through 5 columns arranged in series packed with immobilised enzyme. The temperature of the reaction was maintained at 50°C. The end product was analysed for the formation of (-)-menthyl acetate by GC analysis. Of the available (-)-menthol, 100% was converted to (-)- menthyl acetate at an ee of 98%. In a 206 day period an amount of (-)-menthyl acetate equivalent to 101g of menthol per gram of immobilized enzyme was produced by this immobilized enzyme system.
Example 6 } A solution of methanol (50,1 g), water (50,21 g) and NaOH (6,03 g, 0,15 mol) was placed in a reactor and heated to 60°C. (-)-Menthyl acetate (30,53 g, 15 mol) was then added to the reactor and the reaction was vigorously stirred for minutes. Qualitative GC analysis indicated a 53 area % menthy! acetate and a 47 area % menthol.
Example 7 (-)-Menthol (100 g) and Ni (1%) were placed in round bottom flask and heated at reflux for 2 hours. Once cooled to 25°C, the reaction mixture was sampled.
Quantitative m/m analysis 17% thymol, 23% menthols and 54% menthones with a % (+)-menthol/(x)-menthol of 22%.
Claims (19)
- CLAIMS 1 A process of separating a single desired stereoisomer from a racemic mixture of eight stereoisomers of a compound of the formula Ill OH Ry HI wherein R; represents an isopropanol group, an isopropyl group or an isopropylene group, including the steps of:(1) contact the racemic mixture in a suitable organic solvent with an esterifying agent and a stereospecific enzyme which stereoselectively esterifies the -OH group of the desired stereoisomer, for a time sufficient to convert a desired percentage of the desired stereoisomer to a compound of the formula IVJR o Rs R4 Iv wherein R, is as defined above and R4 is an alkyl or an aryl group,to give a first reaction product including the compound of the ) formula IV, the organic solvent, the unconverted stereoisomers of the compound of the formula Ill, excess esterifying agent and by- products of the reaction; and (2) separating the compound of the formula IV from the first reaction product.
- 2 A process according to claim 1 wherein step (2) comprises the sub-steps of:(2)(a) separating the first reaction product from the enzyme;(2)(b) removing from the first reaction product the organic solvent, the excess esterifying agent, and the by-products of the reaction to give a second reaction product including the compound of the formula 1V and the unconverted stereoisomers of the compound of formula lil ; and(2)(c) separating the compound of the formula IV from the second reaction product leaving a third reaction product containing the unconverted stereoisomers of the compound of the formula Ill.
- 3 A process according to claim 1 or claim 2 including the step, after step(2) of:(3) racemizing the unconverted stereoisomers of the compound of the formula lll in the third reaction product to give a fourth reaction product containing a mixture of all eight stereoisomers of the compound of the formula Ill and recycling the fourth reaction product to step (1).
- 4 A process according to claim 3 including the step, after step (3) of: (4) hydrolysing the compound of the formula IV to give the desired stereoisomer of the compound of the formula Ill.
- A process according to claim 4 wherein when R; is an isopropanol group ] or an isopropylene group, before or after step (4), the compound of the formula IV or the desired stereoisomer of the compound of the formula lil is subjected to a reduction step to convert Ry to an isopropyl group.
- 6 A process according to any one of claims 1 to 5 including the following steps, prior to step (1) of: (a) reacting a compound of the formula Ra “OR; wherein R, represents a methyl or a hydroxymethyl group, and Rj represents H, a base metal, a benzyl group or an allyl group, with an alkylating agent in the presence of a catalyst to give a compound of the formula li Ra “OR; Ry ‘ It wherein Ry is as defined in claim 1 and R, and Rj are as defined above; and(b) hydrogenating the compound of the formula il in the presence of a catalyst to give a racemic mixture of the eight stereoisomers of the compound of the formula Hl.
- 7 A process according to any one of claims 1 to 6 wherein in step (1) the solvent is selected from the group consisting of isooctane; n-heptane; decane: methyl cyclohexane; t-butyl methyl ether; xylene; kerosene; pentane; cyclohexane; hexane; benzene; butanol; toluene; isopropanol; ethyl lactate; and acetone.
- 8 A process according to claim 7 wherein in step (1) the solvent is n- heptane.
- 9 A process according to any one of claims 1 to 8 wherein in step (1) the esterifying agent is selected from the group consisting of vinyl acetate, butyl acetate, octanoic acid, isopropenyl acetate, vinyl butyrate, ethyl lactate and ethyl acetate.
- A process according to claim 9 wherein in step (1) the esterifying agent is vinyl acetate.
- 11 A process according to any one of claims 1 to 10 wherein in step (1) the esterifying agent is used in a molar ratio to the desired stereoisomer of the compound of the formula Ill of 0,5:1 to 30:1 inclusive.
- 12 A process according to any one of claims 1 to 11 wherein in step (1) the stereospecific enzyme is selected from the group consisting of Candida cylindracea lipase, lipase Hog pancreas, lipase Pseudomonas fluorescens, lipase Aspergillus oryzae, lipase Rhizopus niveus, lipase Rhizomucor miehei, lipase Candida antarctica, lipase Mucor javanicus, lipase Rhizopus arrhizus, lipase Penicillium roqueforti, lipase Candida lipolytica, lipoprotein lipase Pseudomonas sp., type B, lipoprotein lipase) Pseudomonas cepacia, lipoprotein lipase Chromobacterium viscosum, esterase Bacillus thermoglucosidasius, esterase Bacillus stearothermophilus, esterase Mucor miehei, esterase hog liver, Candida rugosa lipase, lipase Mucor miehei, Candida antarcitica B lipase, Candida antarctica A lipase, Chiro-CLEC-CR, Chiro-CLEC-CR (slurry), porcine liver esterase, Penicillin acylase, Subtilisin Carlsberg, Chiro- CLEC-BL (slurry), Chiro-CLEC-PC (slurry), Chiro-CLEC-EC (slurry), . Aspergillus oryzae protease, PeptiCLEC-TR (slurry), ESL-001-01, ESL- 001-01 with stabiliser, ESL-001-02, ESL-001-03, ESL-001-05, Chirazyme L4 (Pseudomonas sp.), Chirazyme L5 (Candida antarctica fraction A), Chirazyme L1 (Burkholderia), Chirazyme L6 (Porcine pancreas), Chirazyme L7, Chirazyme L8, Naproxen esterase, Lipomax, Genzyme, Lipoprotein lipase, Novozyme 868, Novozyme 435, immobilised Candida antarctica lipase, Nagase enzyme, Lipase A-10FG (Rhizopus javanicus), Amano AYS, Amano PS, Amano PSD, Amano AKD11, and Amano AKD111.
- 13 A process according to any one of claims 1 to 12 wherein in step (1) the enzyme is Amano AK lipase enzyme.
- 14 A process according to any one of claims 1 to 13 wherein in step (1) the stereospecific enzyme is used in an amount of from 1g/I to 60g/l inclusive of the mixture of the racemic mixture of the eight stereoisomers of the compound of the formula ll, the suitable organic solvent and the esterifying agent.)
- 15 A process according to any one of claims 1 to 14 wherein step (1) is carried out at a temperature of from 20°C to 100°C inclusive and at atmospheric or higher pressure.*
- 16 A process according to any one of claims 2 to 15 wherein after step A (2)(a) the stereospecific enzyme is recycled to step (1).
- 17 A process according to any one of claims 2 to 15 wherein in step (1) the stereospecific enzyme is used in a continuous system wherein the stereo specific enzyme is retained within a reactor and wherein in step (2)(a) the first reaction product exits the reactor leaving behind the enzyme.
- 18 A process according to any one of claims 4 to 17 wherein in step (4) the hydrolysis is carried out in the presence of a base, in a suitable solvent, and at a temperature below the boiling point of the solvent or the reflux temperature of the mixture of reactants at the pressure at which the reaction is carried out.
- 19 A process according to any one of claims 1 to 18 wherein in the compound the formula lll, Ry represents an isopropy! group.L)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200300125A ZA200300125B (en) | 2000-07-07 | 2003-01-06 | Process for preparing (-)menthol and similar compounds. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200003417 | 2000-07-07 | ||
ZA200300125A ZA200300125B (en) | 2000-07-07 | 2003-01-06 | Process for preparing (-)menthol and similar compounds. |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200300125B true ZA200300125B (en) | 2004-03-16 |
Family
ID=32853691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200300125A ZA200300125B (en) | 2000-07-07 | 2003-01-06 | Process for preparing (-)menthol and similar compounds. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200300125B (en) |
-
2003
- 2003-01-06 ZA ZA200300125A patent/ZA200300125B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4963492A (en) | Method for the enzymatic racemate resolution of racemic alcohols with/in vinyl esters by transesterification | |
AU2001278640B2 (en) | Process for preparing (-)menthol and similar compounds | |
AU2001278640A1 (en) | Process for preparing (-)menthol and similar compounds | |
JPH0856693A (en) | Production of optically active endo-2-norborneols | |
KR100657212B1 (en) | The method of making optically active ester derivatives and their acids from racemic esters | |
US5658796A (en) | Optical resolution of alkyl chroman-2-carboxylates | |
ZA200300125B (en) | Process for preparing (-)menthol and similar compounds. | |
US7582469B2 (en) | Method for enantioselectively opening oxetan-2-ones | |
JPH09501834A (en) | Lipase-catalyzed acylation of alcohols with diketene. | |
EP1290208B1 (en) | Method for optically resolving a racemic alpha-substituted heterocyclic carboxylic acid using enzyme | |
US20040058422A1 (en) | Process for preparing (-)- menthol and similar compounds | |
Bracher et al. | A biocatalytic approach to nonracemic 2-methyl-3-(2-thiophene)-1-propanols as chiral building blocks for the synthesis of pyridine alkaloids | |
KR100651338B1 (en) | Method for preparing optically active R-2-chloromandelic acid and its ester derivatives using Baker's Yeast | |
Kolodiazhna et al. | Synthesis of optically active vicinal fluorocyclopentanols and fluorocyclopentanamines by enzymatic deracemization. | |
EP1349950B1 (en) | A process for the preparation of 1-(3-trifluoromethylphenyl)-propan-2-ol enantiomers | |
JPH1175889A (en) | Production and purification of optically active alpha-trifluoromethyllactic acid and its enantiomer ester | |
KR100758512B1 (en) | The method of preparing optically active 3-hydroxy-3-phenylpropionic acids and optically active 3-acyloxy-3-phenylpropionic acid by enzymatic method | |
EP0783039B1 (en) | Process for producing optically active 2-alkoxycyclohexanol derivatives | |
JPH08113550A (en) | Production of optically active 3-hydroxyhexanoic acids | |
KR100545472B1 (en) | The method of preparing optically active cis-1-Ramino-2-indanol and their esters by enzymatic method | |
JP2003125795A (en) | Method for producing optically active 2-acylthio-3- phenylpropionic acids or optically active 2-mercapto-3- phenylpropionic acids | |
JPH10287620A (en) | Optically active methylsuccinic ester, and its production | |
JP2006014636A (en) | Method for producing acyl derivative | |
JPH09107989A (en) | Production of optically active compound | |
JPH1180113A (en) | Optically active beta-cyanoisobutyric acids and their production |